Review Papers Claim by Claim

1) GLP‑1, gastrin and renal sodium handling

Afsar et al. summarize animal and cell studies showing GLP‑1 receptor activation reduces NHE3 activity in proximal tubule, increasing natriuresis, and GLP‑1 receptor agonists (or DPP‑4 inhibition) lower BP in several rodent models and some human studies of obese/T2DM patients; gastrin via CCKBR is implicated in renal natriuresis and knockout models develop salt‑sensitive hypertension. These mechanisms are plausible and supported by multiple experimental reports, but many are preclinical or small human studies, limiting generalizability.
Afsar et al., JASH 2016 — GLP‑1 & gastrin review

2) Gut microbiota metabolites → blood pressure

The review accurately highlights SCFAs (acetate, propionate, butyrate) acting via GPR41/GPR43 and Olfr78 with potentially opposing BP effects (vasodilation vs renin release). It also flags TMAO and protein‑fermentation toxins as CKD‑relevant. Subsequent literature (animal FMT and observational human cohorts) strengthens the microbiota→BP link, but heterogeneity in taxa signatures and human causality remains unresolved.
Pluznick et al., Circ Res 2017 — microbiota metabolites

3) Intestinal sodium absorption — NHE3 inhibition as therapy

The paper emphasizes NHE3 blockade (tenapanor, SAR218034) to reduce intestinal Na+ uptake and lower SBP in rat models; tenapanor increased fecal sodium and decreased urinary sodium in human volunteer studies but caused osmotic stools and showed 'escape' over weeks—likely compensatory intestinal adaptations (ENaC upregulation). The review correctly flags RAAS activation and acid‑base concerns in renal impairment as outstanding clinical safety questions.
Afsar et al., JASH 2016 — NHE3 inhibitors

4) Strengths of the review

• Integrative: connects endocrinology (GLP‑1, gastrin), microbiology (SCFAs, TMAO), renal physiology (NHE3) and pharmacology.
• Broad citation base (53 refs) spanning mechanistic animal work, cell studies and early human experiments.
• Clinical translational emphasis—explicitly discusses ongoing trials and safety considerations (e.g., tenapanor in CKD).

5) Weaknesses, blind spots & biases

• Narrative design: no systematic search strategy or meta‑analysis — selection bias and positive‑result emphasis are possible.
• Overreliance on animal data: many mechanistic claims rely on rodent models (Dahl, SHR, Dahl SS), which differ from human physiology and diet.
• Limited human outcome data: clinical BP/renal outcome trials for NHE3 inhibitors and microbiome interventions were not available or were underpowered at time of review.
• Mechanistic complexity: SCFA receptor effects are receptor- and tissue-dependent (GPR41 vs Olfr78) producing opposing BP changes; review reports this but cannot resolve net human effect.
• Safety considerations: diarrhea/osmotic stool, RAAS activation, acid‑base changes in CKD — all need controlled long-term monitoring.

6) Where the conclusion could be falsified

The core causal claims would be falsified if well-powered, randomized human trials of (a) GLP‑1 receptor agonists or gastrin modulators failed to change natriuresis/BP, (b) NHE3 inhibitors failed to reduce ambulatory BP or caused unacceptable compensatory mechanisms (no net sodium balance change), or (c) rigorous human microbiome manipulations (FMT, targeted enzyme inhibitors) failed to alter BP or renal outcomes after controlling for diet/medications.